Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

Amgen and Novartis abandon Alzheimers drug after worsening symptoms

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

David Reese. "Our team joins the millions whose lives are impacted by Alzheimer's disease in our disappointment that the Generation Program did not yield a treatment for Alzheimer's disease ... Nevertheless David Reese says: "We still believe amyloid

Latest news

  • Boehringer tests speech as early warning for CNS diseases Boehringer tests speech as early warning for CNS diseases

    Company extends foray into digital health innovation. Boehringer Ingelheim is working on a speech analysis app that it hopes could eventually detect diseases like schizophrenia or Alzheimer’s disease. ... Schizophrenia and Alzheimer’s dementia are

  • AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy AmyPore gets EU backing for Alzheimers and Parkinson’s therapy

    Alzheimer’s and Parkinson’s disease. ... The peptide – called AmyP53 – targets receptors on nerve cells called gangliosides that attract and bind amyloid proteins that are thought to be linked to the pathology of both Alzheimer’s (beta

  • Bicycles Therapeutics enters dementia discovery with venture capital fund Bicycles Therapeutics enters dementia discovery with venture capital fund

    The last decade has been characterised by a disheartening string of late-stage drug failures in Alzheimer’s disease, and this year alone has seen two major programmes crash in the ... Researchers working in the field know that new approaches must be

  • Lundbeck snaps up Abide Therapeutics for $400m Lundbeck snaps up Abide Therapeutics for $400m

    challenging. Efforts to bring forward its own drugs have been undermined by a couple of late-stage failures, including idalopirdine for Alzheimer’s disease and Lu AF35700 for treatment-resistant schizophrenia. ... agreed a $1.1bn deal last year to buy

  • Biogen’s tofersen shows promise in slowing down ALS Biogen’s tofersen shows promise in slowing down ALS

    Biogen is on the look out for strong candidates to boost its prospects, especially after recently conceding defeat on one of its biggest pipeline hopes aducanumab in Alzheimer’s disease. ... Michael Ehlers recently said the company won’t give up on

More from news
Approximately 51 fully matching, plus 313 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimers disease R&D?

    How past failures and emerging biology are reshaping drug development. Over the past 15 years, the best-resourced drug development teams on earth have spent billions on Alzheimer’s disease. ... And there is scope to improve the lives of Alzheimer’s

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimers drug discovery

    A phase I dose escalation study of AL002 for patients with Alzheimer’s disease, as part of a global strategic partnership with AbbVie, is ongoing. ... Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders,

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimers disease – is Europe prepared if a breakthrough treatment becomes available?

    Currently, there is no Alzheimer’s disease- modifying treatment available but there are several therapies in development. ... If appropriate, they would be referred to treatment, which would reduce the risk of progression from MCI to manifest dementia

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s.The anti-Parkinson medications available primarily promote dopamine levels in the brain to compensate for the loss of ... The design of such neuroprotective

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Option exercise (2 options). 640.

More from intelligence
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • Diagnosing the lag in neuropsychiatric treatments

    Europe spends £690 billion a year on brain disorders, more than both cardiovascular disease and oncology combined. ... Neurological and psychiatric disorders (collectively known as neuropsychiatric disorders), such as Alzheimer’s disease and

  • 'Fake news': battling misinformation in healthcare

    An article published just three days later, again from ‘The Telegraph’ , plays on the  growing threat of Alzheimer’s. ... The article is entitled ‘Alzheimer’s disease can be spotted through simple eye test’ and whilst this article is based

  • Havas Lynx shines a spotlight on carers

    Commenting on the white paper’s findings, Havas Lynx CEO, Dave Hunt, said:. ... References:. Alzheimer’s Disease International (2013) http://bit.ly/2nPw6QK (Accessed April 2017). Carers UK (2015)   (Accessed April 2017).

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Please contact us at info@random42.com to arrange a meeting. For more information on Random42’s capabilities please see

  • The dark side of direct-to-consumer genetic tests

    Instead,   they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

More from PMHub
Approximately 2 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics